Fabry disease: Demographic data since introduction of enzyme replacement therapy;Morbus fabry: Demografische übersicht seit einführung der enzymersatztherapie

Deutsche Medizinische Wochenschrift

Volumn 132, Issue 28-29, 2007, Pages 1505-1509

  Cybulla, Markus ^a   Walter, K ^a   Neumann, H P H ^a   Widmer, U ^b   Scharer M ^b   Sunder Plassmann, G ^c   Jansen, T ^d   Rolfs, A ^e   Beck, M ^f  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY OF ROSTOCK   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

galaktosidase A; Enzyme replacement therapy; Fabry disease; Fabry outcome survey

Indexed keywords

AGALSIDASE ALFA;

ADULT; ANHIDROSIS; ARTHRALGIA; ARTICLE; AUSTRIA; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; FEVER; GERMANY; HEALTH SURVEY; HEMANGIOKERATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PARESTHESIA; SCORING SYSTEM; SWITZERLAND; ADOLESCENT; AGED; CHILD; INCIDENCE; MIDDLE AGED; MORTALITY; REGRESSION ANALYSIS; SURVIVAL;

ADOLESCENT; ADULT; AGED; AUSTRIA; CHILD; FABRY DISEASE; FEMALE; GERMANY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SURVIVAL ANALYSIS;

EID: 34547200495     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-982060     Document Type: Article

References (19)

1. Beck M, Ricci R, Widmer U et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004; 34: 838-844
2. Brady RO, Gal AE et al. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276: 1163-1167
3. Brady RO, Tollman JF, Johnson WG et al. Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease. N Engl J Med 1973; 289: 9-14
4. Desnick RJ, Schuchman EH. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet 2002; 3: 954-966
5. Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16
6. Galanos J, Nicholls K, Grigg L et al. Clinical features of Fabry's disease in Australian patients. Intern Med J 2002; 32: 575-584
7. Guffon N. Clinical presentation in female patients with Fabry disease. J Med Genet 2003; 40: e38
8. K/DOQI. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1-266
9. Levey AS. Clinical practice. Nondiabetic kidney disease. N Engl J Med 2002; 347: 1505-1511
10. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38: 750-760
11. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769-775
12. Maier EM et al. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl 2006; 95: 30-38
13. Mehta A, Ricci R, Widmer U et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34: 236-242
14. Mehta A, Beck M, Ricci R et al. Fabry outcome survey: need for documentation of dermatological, ophthalmologic and psychiatric affections: authors' reply. Eur J Clin Invest 2004; 34: 517
15. Schiffmann R, Kopp JB, 3rd Austin HA et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. Jama 2001; 285: 2743-2749
16. Siamopoulos KC. Fabry disease: kidney involvement and enzyme replacement therapy. Kidney Int 2004; 65: 744-753
17. Sunder-Plassmann G, Födiger M. Diagnosis of Fabry disease: the role of screening and case-finding studies. 1st ed, Oxford, UK, In: A. Mehta, M. Beck, G. Sunder-Plassmann (eds.): Fabry disease: Perspectives from 5 years of FOS. 2006: 163-168
18. Whybra C, Kampmann C, Willers I et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001; 24: 715-724
19. Whybra C, Kampmann C, Krummenauer F et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004; 65: 299-307